Biomarkers and Adverse Outcome Pathways

Biomarkers are measurable indicators of biological processes, exposures, or effects, and in toxicology they are used to detect, quantify, and interpret the response of an organism to a harmful agent. Adverse outcome pathways (AOPs) are structured frameworks that connect a molecular initiating event through a sequence of key biological steps to an adverse outcome of regulatory concern, providing the mechanistic backbone that gives biomarkers their interpretive meaning.

Definition

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention; an adverse outcome pathway is a conceptual construct that organises existing mechanistic knowledge linking a molecular initiating event, via measurable key events, to an adverse outcome relevant to risk assessment.

Scope

The entry covers the definition and classification of biomarkers (of exposure, effect, and susceptibility), their use as endpoints in toxicity testing, and the adverse outcome pathway framework that links mechanistic events to outcomes. It explains how biomarkers and AOPs help integrate in vitro, animal, and human data. It is a methodological and conceptual topic and does not provide diagnostic thresholds or clinical interpretation for specific markers.

Core questions

• What does a given biomarker indicate, exposure, effect, or susceptibility?
• How can biomarkers be qualified and validated for use in toxicity assessment?
• How does an adverse outcome pathway connect molecular events to an outcome of concern?
• How do biomarkers and AOPs help integrate mechanistic and in vitro data into risk assessment?

Key concepts

• Biomarkers of exposure, effect, and susceptibility
• Molecular initiating event
• Key events and key event relationships
• Adverse outcome of regulatory relevance
• Biomarker qualification and validation
• Surrogate endpoints
• Integration of in vitro and in vivo evidence

Key theories

Adverse Outcome Pathway framework

A structured way of organising mechanistic evidence as a sequence from a molecular initiating event through measurable key events to an adverse outcome, with defined key event relationships, intended to make mechanistic and in vitro data usable for regulatory toxicology.

Mechanisms

Biomarkers are classified by what they reflect: biomarkers of exposure (an agent or its metabolite, or its molecular interaction), biomarkers of effect (a measurable biochemical or physiological change indicating harm), and biomarkers of susceptibility (factors that modify the response). The adverse outcome pathway framework arranges mechanistic knowledge as a chain that begins with a molecular initiating event, the first interaction between a substance and a biological target, proceeds through a series of measurable key events at increasing levels of biological organisation, and ends in an adverse outcome relevant to regulatory decisions. Biomarkers map onto these key events, allowing data from cell-based assays and animal or human studies to be aligned along a common mechanistic axis and integrated into a weight-of-evidence assessment.

Clinical relevance

Biomarkers and adverse outcome pathways increasingly inform how the safety of drugs and chemicals is evaluated and how mechanistic and non-animal evidence is interpreted. Understanding these concepts supports critical appraisal of mechanistic safety data. The entry is descriptive of methodology and concepts and is not a basis for interpreting biomarker results in individuals or for clinical decisions.

Evidence & guidelines

The biomarker terminology framework set out by the Biomarkers Definitions Working Group has been widely adopted, and regulatory agencies operate formal biomarker qualification processes. The adverse outcome pathway concept, introduced by Ankley and colleagues in 2010, is supported by an international knowledge base (the AOP-Wiki and OECD AOP programme) and is referenced in evolving guidance on integrated approaches to testing and assessment. These frameworks are developing and not yet a uniform regulatory standard across all endpoints.

History

Biomarkers have a long history in clinical chemistry and occupational medicine, but their conceptual framework was consolidated by the Biomarkers Definitions Working Group in 2001, which standardised the distinctions between biomarkers, surrogate endpoints, and clinical endpoints. The adverse outcome pathway concept emerged from ecotoxicology with Ankley and colleagues' 2010 formulation and was subsequently developed as a general tool for organising mechanistic toxicology, as discussed by Vinken, aligning with the mechanism-focused reorientation called for by the National Research Council in 2007.

Debates

How much regulatory weight can adverse outcome pathways and associated biomarkers carry?

AOPs offer a transparent way to integrate mechanistic and in vitro data, but most pathways are incompletely characterised, and there is ongoing discussion about the level of confidence and completeness required before they can drive regulatory decisions rather than support them.

Key figures

• Gerald Ankley
• Mathieu Vinken

Seminal works

• biomarkers-wg-2001
• ankley-2010
• vinken-2013

Frequently asked questions

What is the difference between a biomarker of exposure and a biomarker of effect?

A biomarker of exposure indicates that an agent has entered the body (for example the agent or its metabolite), whereas a biomarker of effect indicates a measurable biological change resulting from that exposure. They answer different questions: whether exposure occurred versus whether harm is developing.

What is a molecular initiating event in an adverse outcome pathway?

It is the first interaction between a substance and its biological target that starts the chain of events leading to an adverse outcome. It anchors the pathway and is the point at which mechanistic, often in vitro, evidence enters the framework.